SCHEDULE: Vivo Capital Reduces Stake in IO Biotech Below 5%
Beneficial Ownership Amendment
Vivo Capital entities have filed an amended Schedule 13G, reporting their beneficial ownership in IO Biotech, Inc. has fallen below the 5% threshold.
Summary
- Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. now report 0% beneficial ownership in IO Biotech, Inc.
- Vivo Opportunity, LLC and Vivo Opportunity Fund Holdings, L.P. each report beneficial ownership of 3,157,894 shares, representing 4.6% of IO Biotech's common stock.
- The 3,157,894 shares are issuable upon the exercise of certain warrants.
- The calculation of the 4.6% ownership is based on 65,880,914 shares outstanding as of August 11, 2025, plus the 3,157,894 shares issuable from warrants.
- This filing is an Amendment No. 1, indicating a change from a previous filing where beneficial ownership was above 5%.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a significant institutional investor has reduced its stake below the 5% reporting threshold, which could be perceived as a decrease in confidence or a strategic divestment, although it is a factual disclosure without explicit negative language.
Positives
- NA
Negatives
- A significant institutional investor, Vivo Capital, has reduced its beneficial ownership in IO Biotech, Inc. to below the 5% threshold, which could be interpreted as a decrease in conviction or a portfolio rebalancing.
- Two of the reporting entities, Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P., no longer hold any beneficial ownership.
Risks
- The reduction in a significant investor's stake could lead to negative market perception regarding institutional confidence in IO Biotech, Inc.'s future prospects.
- A decrease in institutional ownership might reduce the stability of the shareholder base.
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing is a standard disclosure of a change in beneficial ownership by an institutional investor in a biotechnology company. It does not provide specific industry context beyond the company's sector.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: May perceive a reduction in institutional confidence due to Vivo Capital's decreased stake, potentially influencing stock price.
- Management: May face questions regarding the reasons for the reduction in a significant investor's position.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date as of which 65,880,914 shares of Common Stock were reported outstanding in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-08-14 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-09-30 | Date of event which requires filing of this statement (ownership dropped below 5%). |
| 2025-11-14 | Signature date for the Schedule 13G Amendment No. 1 filing. |
Recommendation
holdThe filing indicates a significant institutional investor, Vivo Capital, has reduced its beneficial ownership in IO Biotech, Inc. to below the 5% threshold. While not a direct 'sell' signal, the reduction in a major holder's stake could be interpreted as a lack of stronger conviction or a portfolio rebalancing. This information alone does not provide sufficient grounds for a 'buy' or 'strong sell' recommendation, but it warrants a 'hold' and further monitoring of the company's performance and other institutional ownership changes.
Keywords
IO Biotech, Vivo Capital, Schedule 13G, Beneficial Ownership, Equity Stake, Warrants, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.